Aid for AIDS

universal_treatment

May 27, 08

AID FOR AIDS sends El Salvador and Costa Rica more than $50,000 worth of antiretroviral meds

International organization continues to show its dedication to improving the quality of life for people living with HIV and AIDS in developing countries.

NEW YORK, NY (JULY 11, 2007): This week AID FOR AIDS continued demonstrating its dedication to improving the quality of life for individuals living with HIV and AIDS in developing countries.  The non-profit organization donated more than 5,700 bottles of antiretroviral medication to the governments of El Salvador and Costa Rica.  This medication, worth more than $50,000 (USD), will be distributed by the National AIDS Program in El Salvador and by the Department of Social Security in Costa Rica.

Specifically, El Salvador is receiving 4,000 bottles of Avocomb (Lamivudine + Zidovudine) and over 700 bottles of Avolam (Lamivudine).  Costa Rica is receiving 1,000 bottles of Avostav (Stavudine).  The medications are generic formularies manufactured by the Indian Pharmaceutical company Ranbaxy.
The shipment to El Salvador represents one-third of the total medication that will be donated to the country this summer.  AID FOR AIDS will provide the annual treatment for 400 individuals living with HIV and AIDS in El Salvador.  Recipients of this medication will be members of the ‘mobile population’- individuals who move from one place to another, temporarily, seasonally, or permanently, for various voluntary and/or involuntary reasons.  These individuals represent a particularly vulnerable population due to their mobility and economic instability. 

In total, AID FOR AIDS will not only provide medication for these 400 individuals, but is also donating an additional 40,000 bottles of medication to be used to provide treatment to the general population receiving antiretroviral medication in El Salvador.  This medication will be donated in three separate shipments, all scheduled to be sent this summer.

Author: Tobey Busch, MPH

For more information about this program please contact Tobey Busch, Director of the Universal Treatment Access Initiative at (212) 337-8043 or


image